Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatitis A|Hepatitis C, Chronic|HIV Infections|Acquired Immunodeficiency Syndrome|Hepatitis C|Liver Cirrhosis
Phase 2: Hepatitis A|Hepatitis C, Chronic|Hepatitis C
Phase 1: Hepatitis A|Hepatitis C, Chronic|Hepatitis C|Healthy Volunteers|HIV Infections|Liver Cirrhosis|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02114671 |
NCT02114671 | P1 |
Withdrawn |
Healthy Volunteers |
2014-10-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT02016625 |
NCT02016625 | P1 |
Completed |
Healthy Volunteers |
2014-04-01 |
2024-06-26 |
Primary Endpoints|Treatments |
|
NCT01965431 |
NCT01965431 | P1 |
Completed |
Healthy Volunteers |
2014-01-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT01941615 |
NCT01941615 | P1 |
Terminated |
Healthy Volunteers |
2014-01-01 |
2019-03-20 |
Treatments |
|
NCT02716428 |
TRK-450-0203 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2017-09-01 |
2019-03-20 |
Treatments |
|
NCT02593162 |
TRK-450-0201 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2016-12-01 |
2019-03-20 |
Treatments |
|
2012-003534-17 |
2012-003534-17 | P2 |
Completed |
Hepatitis C, Chronic |
2016-06-08 |
2022-03-13 |
Treatments |
|
2009-018197-66 |
2009-018197-66 | P2 |
Completed |
Hepatitis C, Chronic |
2014-10-30 |
2022-03-13 |
Treatments |
|
NCT01132313 |
Randomized Phase Ib/II | P2 |
Completed |
Hepatitis C, Chronic |
2014-10-01 |
2019-03-19 |
||
NCT01830127 |
HCVerso3 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2014-10-01 |
2019-03-19 |
Treatments |
|
NCT01859962 |
HCV Genotype 1a | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2014-05-01 |
2019-03-19 |
||
NCT01608737 |
NCT01608737 | P3 |
Withdrawn |
Hepatitis A|Hepatitis C, Chronic |
2015-10-01 |
2019-03-19 |
||
2012-003533-41 |
2012-003533-41 | P3 |
Completed |
Liver Cirrhosis |
2015-01-22 |
2022-03-13 |
Treatments |
|
NCT01732796 |
HCVerso1 | P3 |
Completed |
Hepatitis C, Chronic |
2015-01-01 |
2019-03-19 |
Treatments |
|
2012-003535-27 |
BI207127 in combination with faldaprevir and ribavirin in treatment naive HCV GT1 infected patients | P3 |
Completed |
Hepatitis C, Chronic|Liver Cirrhosis |
2014-11-16 |
2022-03-13 |
Treatments |
|
2010-021734-59 |
2010-021734-59 | P3 |
Completed |
Hepatitis C, Chronic|HIV Infections |
2014-06-10 |
2025-07-01 |
Treatments |
|
2011-000141-20 |
2011-000141-20 | P3 |
Completed |
Hepatitis C |
2014-06-10 |
2022-03-13 |
Treatments |
|
NCT01330316 |
NCT01330316 | P3 |
Completed |
Hepatitis C|Hepatitis A |
2014-06-01 |
2019-03-19 |
Treatments |
|
JapicCTI-121756 |
JapicCTI-121756 | P3 |
Completed |
Hepatitis C, Chronic |
2014-06-01 |
|||
2010-021715-17 |
BI 201335 in TE patients | P3 |
Completed |
Hepatitis C, Chronic |
2014-05-15 |
2022-03-13 |
||
JapicCTI-111528 |
JapicCTI-111528 | P3 |
Completed |
Hepatitis C, Chronic |
2014-04-01 |
|||
NCT01297270 |
STARTverso 2 | P3 |
Completed |
Hepatitis C|Hepatitis A |
2014-04-01 |
2019-03-19 |
Treatments |
|
2010-021716-42 |
2010-021716-42 | P3 |
Completed |
Hepatitis C, Chronic |
2014-03-12 |
2022-03-13 |
Treatments |
|
NCT01343888 |
STARTverso 1 | P3 |
Completed |
Hepatitis A|Hepatitis C |
2014-03-01 |
2019-03-19 |
Treatments |
|
NCT01728324 |
HCVerso2 | P3 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2014-02-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/30/2023 |
PubMed |
Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections. |
|
01/01/2012 |
PubMed |
Protease Inhibitors (HCV). |